Proteases as anti-cancer targets - Molecular and biological basis for development of inhibitor-like drugs against cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 7, 2009, Pages 728-762

  Bialas A ^a   Kafarski, P ^a  

^a WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Anti cancer; Cathepsins; Inhibitors; Matriptase; Mechanism based; MMPs; Proteases; Proteasome; Selectivity; uPA

Indexed keywords

3 AMIDINOPHENYLALANINE DERIVATIVE; ALOXISTATIN; AMILORIDE; B 636; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; BOWMAN BIRK INHIBITOR; CARBAMIC ACID DERIVATIVE; CATHEPSIN INHIBITOR; CGS 27023A; MATRIPTASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; N ARYLSULFONYL N ALKOXYACETOHYDROXAMIC ACID; PHENYLGUANIDINE DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR; PRINOMASTAT; PROTEINASE INHIBITOR; SUNFLOWER TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; CARCINOGENESIS; CHEMICAL MODIFICATION; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR MODEL; MULTIPLE MYELOMA; MUSCULAR DYSTROPHY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN METABOLISM; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TERATOGENICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS;

EID: 73449102130     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789056877     Document Type: Review

References (247)

1. Jedinák, A.; Maliar, T. Inhibitors of proteases as anticancer drugs. Neoplasma, 2005, 52(3), 185-92.
2. Lee, M.; Freedman, R.; Mobashery, S. Extracellular proteases as targets for treatment of cancer metastases. Chem. Soc. Rev., 2004, 33(7), 401-409.
3. Mittl, P.R.E.; Grütter, M.G. Opportunities for structure-based design of protease-directed drugs. Curr. Opin. Struct. Biol., 2006, 16(6), 769-775.
4. Fear, G.; Komarnytsky, S.; Raskin, I. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol. Ther., 2007, 113(2), 354-368.
5. Winum, J.Y.; Scozzafava, A.; Montero, J.L.; Supuran, C.T. Sul-famates and their therapeutic potential. Med. Res. Rev., 2005, 25(2), 186-228.
6. Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C.T. Anti-cancer and antiviral sulfonamides. Curr. Med. Chem., 2003, 10(11), 925-953.
7. Ilies, M.A.; Scozzafava, A.; Supuran, C.T. Therapeutic applications of serine protease inhibitors. Expert Opin. Ther. Pat., 2002, 12(8), 1181-1214.
8. Schmitt, M.; Wilhelm, O.G.; Reuning, U.; Krüger, A.; Harbeck, N.; Lengyel, E.; Graeff, H.; Gänsbacher, B.; Kessler, H.; Bürgle, M.; Stürzebecher, J.; Sperl, S.; Magdolen, V. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteolysis, 2000, 14(2/3), 114-132.
9. Steinmetzer, T. Synthetic urokinase inhibitors as potential antitumor drugs. IDrugs, 2003, 6(2), 138-146.
10. Madsen, M.A.; Deryugina, E.I.; Niessen, S.; Cravatt, B.F.; Quigley, J.P. Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation. J. Biol. Chem., 2006, 281(23), 15997-16005.
11. Doherty, T.M.; Asotra, K; Pei; D.Q.; Uzui, H.; Wilkin, D.J.; Shah, P.K.; Rajavashisth, T.B. Therapeutic developments in matrix metalloproteinase inhibition. Expert Opin. Ther. Pat., 2002, 12(5), 665-707.
12. Khasigov, P.Z.; Podobed, O.V.; Ktzoeva, S.A.; Gatagonova, T.M.; Grachev, S.V.; Shishkin, S.S.; Berezov, T.T. Matrix metalloproteinases of normal human tissues. Biochemistry (Moscow), 2001, 66(2), 130-140.
13. Ludwig, T. Local proteolytic activity in tumor cell invasion and metastasis. BioAssays, 2005, 27(11), 1181-1191.
14. van Hinsbergh, V.W.M.; Engelse, M.A.; Quax, P.H.A. Pericellular proteases in angiogenesis and vasculogenesis. Arteriosc. Thromb. Vasc. Biol., 2006, 26(4), 716-728.
15. Lee, M.; Fridman, R.; Mobashery, S. Extracellular proteases as targets for treatment of cancer metastases. Chem. Soc. Rev., 2004, 33(7), 401-409.
16. Turk, B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov., 2006, 5(9), 785-799.
17. Koblinski, J.E.; Ahram, M. Sloane, B.F. Unraveling the role of proteases in cancer. Clin. Chim. Acta, 2000, 291(2), 113-135.
18. Elvin, P.; Garner, A.P. Tumour invasion and metastasis: challenges facing drug discovery. Curr. Opin. Pharm., 2005, 5(4), 374-381.
19. Tortora, G.; Melisi, D.; Ciardiello, F. Angiogenesis: a target for cancer therapy. Curr. Pharm. Des., 2004, 10(1), 11-26.
20. Hanahan D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
21. Gullino, P.M. Angiogenesis and oncogenesis. J. Natl. Cancer. Inst., 1978, 61(3), 639-643.
22. Bouck, N.; Stellmach, V.; Hsu, S.C. How tumors become angiogenic. Adv. Cancer. Res., 1996, 69, 135-174.
23. Coussens, L.M.; Raymond, W.W.; Bergers, G.; Laig-Webster, M.; Behrendtsen, O.; Werb, Z. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes. Dev., 1999, 13(11), 1382-1397.
24. Del Rosso, M.; Fibbi, G.; Pucci, M.; D'alessio, S.; Del Rosso, A.; Magnelli, L.; Chiarugi, V. Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin. Exp. Metastasis, 2002, 19(3), 193-207.
25. Fish, P.V.; Barber, C.G.; Brown, D.G.; Butt, R.; Collis, M.G.; Dickinson, R.P.; Henry, B.T.; Horne, V.A.; Huggins, J.P.; King, E.; O'Gara, M.; McCleverty, D.; McIntosh, F.; Phillips, C.; Webster, R. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J. Med. Chem., 2007, 50(10), 2341-2351.
26. Andreasen, P.A.; Egelund, R.; Petersen, H.H., The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci., 2000, 57(1), 25-40
27. Dano, K.; Behrendt, N.; Hoyer-Hansen, G.; Johnsen, M.; Lund, L.R.; Ploug, M.; Romer, Plasminogen activation and cancer. J. Thromb. Haemost., 2005, 93, 676-681.
28. Sidenius, N.; Blasi, F. The urokinase plasminogen activator system in cancer: recent advances and implications for prognosis and therapy. Cancer Metastasis Rev., 2003, 22(2-3), 205-222.
29. Petranka, J.; Zhao, J.; Norris, J.; Tweedy, N.B.; Ware, R.E.; Sims, P.J.; Rosse, W.F. Structure-function relationships of the complement regulatory protein, CD59. Blood Cells Mol. Dis., 1996, 22(3), 281-296.
30. Lijnen, H.R.; Van Hoef, B.; Nelles, L.; Collen, D. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740 - Ala) and plasmin-resistant scu-PA (Lys158-Glu). J. Biol. Chem., 1990, 265(9), 5232-5236.
31. Dano, K.; Andreasen, P.A.; Grondahl-Hansen, J.; Kristensen, P.; Nielsen, L.S.; Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 1985, 44, 139-266.
32. Lee, S.L.; Dickson, R.B.; Lin, C.Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem., 2000, 275(47), 36725.
33. Takeuchi, T.; Harris, J.L.; Huang, W.; Yan, K.W.; Coughlin, S.R.; Craik, C.S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem., 2000, 275(34), 26333-26342.
34. Kobayashi, H.; Schmitt, M.; Goretzki, L.; Chucholowski, N.; Calvete, J.; Kramer, M.; Gunzler, W.A.; Janicke, F.; Graeff, H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J. Biol. Chem., 1991, 266(8), 5147-5152.
35. Goretzki, L.; Schmitt, M.; Mann, K.; Calvete, J.; Chucholowski, N.; Kramer, M.; Gunzler, W.A.; Janicke, F.; Graeff, H. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett., 1992, 297(1-2), 112-118.
36. Parfyonova, Y.V.; Plekhanova, O.S.; Tkachuk, V.A. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Moscow), 2002, 67, 119-134.
37. Yu, H.R.; Schultz, R.M. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res., 1990, 50(23), 7623-7633.
38. Ossowski, L.; Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 1983, 35(3 Pt 2), 611-619.
39. Bauer, T.W.; Liu, W.; Fan, F.; Camp, E.R.; Yang, A.; Somcio, R.J.; Bucana, C.D.; Callahan, J.; Parry, G.C.; Evans, D.B.; Boyd, D.D.; Mazar, A.P.; Ellis, L.M. Targeting of urokinase plazminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met-and insulin-likegrowth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res., 2005, 65, 7775-7781.
40. de Bock, C.E.; Lin, Z.; Itoh, T.; Morris, D.; Murrell, G.; Wang, Y. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. FEBS J., 2005, 272(14), 3572-3582.
41. Min, H.Y.; Doyle, L.V.; Vitt, C.R.; Zandonella, C.L.; Stratton-Thomas, J.R.; Shuman, M.A.; Rosenberg, S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res., 1996, 56(10), 2428-2433.
42. Ploug, M.; Ostergaard, S.; Gardsvoll, H.; Kovalski, K.; Holst-Hansen, C.; Holm, A.; Ossowski, L.; Dano, K. Peptide-derived antagonists of the urokinase receptor affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry, 2001, 40(40), 12157-12168.
43. Almholt, K.; Lund, L.R.; Rygaard, J.; Nielsen, B.S.; Dano, K.; Romer, J.; and Johnsen, M. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int. J. Cancer, 2005, 113(4), 525-532.
44. Gutierrez, L.S.; Schulman, A.; Brito-Robinson, T.; Noria, F.; Ploplis, V.A.; and Castellino, F. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. J. Cancer Res., 2000, 60, 5839-5847.
45. Schweinitz, A.; Steinmetzer, T.; Banke, I.J.; Arlt, M.J.E.; Sturzebecher, A.; Schuster, O.; Geissler, A.; Giersiefen, H.; Zeslawska, E.; Jacob, U.; Kruger, A.; Sturzebecher, J. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J. Biol. Chem., 2004, 279(32), 33613-33622.
46. Joossens, J.; Van der Veken, P.; Surpateanu, G.; Lambeir, A.M.; El-Sayed, I.; Ali, O.M.; Augustyns, K.; Haemers, A. Diphenyl Phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position. J. Med. Chem., 2006, 49(19), 5785-5793.
47. Tamura, S.Y.; Weinhouse, M.I.; Roberts, C.A.; Goldman, E.A.; Masukawa, K.; Anderson, S.M.; Cohen, C.R.; Bradbury, A.E.; Bernardino, V.T.; Dixon, S.A.; Ma, M.G.; Nolan, T.G.; Brunck, T.K. Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10(9), 983-987.
48. Oleksyszyn, J.; Boduszek, B.; Kam, C.M.; Powers, J.C. Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood-coagulation and related serine proteases. J. Med. Chem., 1994, 37(2), 226-231.
49. Belyaev, A.; Zhang, X.M.; Augustyns, K.; Lambeir, A.M.; De Meester, I.; Vedernikova, I.; Scharpe, S.; Haemers, A. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. J. Med. Chem., 1999, 42(6), 1041-1052.
50. Joossens, J.; Van der Veken, P.; Lambeir, A. M.; Augustyns, K.; Haemers, A. Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator. J. Med. Chem., 2004, 47(10), 2411-2413.
51. Magill, C.; Katz, B.A.; Mackman, R.L. Emerging therapeutic targets in oncology: urokinase-type plasminogen activator system. Emerg. Ther. Targets, 1999, 3(1), 109-133.
52. Geratz, J.D.; Shaver, S.R.; Tidewell, R.R. Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and high and low molecular urokinase and on urokinase induced plasminogen activation. Thromb. Res., 1981, 24(1-2), 73-83.
53. Bridges, A.J.; Lee, A.; Schwartz, E.; Towle, M.J.; Littlefield, B.A. The synthesis of three 4-substituted benzo[b]thiophene-2-carboxamides as potent and selective inhibitors of urokinase. Bioorg. Med. Chem., 1993, 1(6), 403-410.
54. Vassalli, J.-D.; Belin, D. Amiloride selectively inhibits the urokinasetype plasminogen activator. FEBS Lett., 1987, 214(1), 187-191.
55. Yang, H.; Henkin, J.; Kim, K.H.; Greer, J. Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. J. Med. Chem., 1990, 33(11), 2956-2961.
56. Barber, C.G.; Dickinson, R.P.; Fish, P.V. Selective urokinasetype plasminogen activator (uPA) inhibitors. Part 3: 1-Isoquinolinylguanidines. Bioorg. Med. Chem. Lett., 2004, 14(12), 3227-3230.
57. Spraggon, G.; Phillips, C.; Nowak, U.K.; Ponting, C.P.; Saunders, D.; Dobson, C.M.; Stuart, D.I.; Jones, E.Y. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure, 1995, 3(7), 681-691.
58. Sanderson, P.E.J. Small, noncovalent serine protease inhibitors. Med. Res. Rev., 1999, 19(2), 179-197.
59. Hopper, J.D.; Clements, J.A.; Quigley, J.P.; Antalis, T.M. Type II transmembrane serine proteases. J. Biol. Chem., 2001, 276(2), 857-860.
60. Takeuchi, T.; Harris, J.L.; Huang, W.; Yan, K.W.; Coughlin, S.R.; Craik, C.S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 2000, 275(34), 26333-26342.
61. Shi, Y.E.; Torri, J.; Yieh, L.; Wellstein, A.; Lippman, M.E.; Dickson, R.B. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res., 1993, 53(66), 1409-1415.
62. Lin, C.-Y.; Wang, J.-K.; Torri, J.; Dou, L.; Sang, Q.A.; Dickson, R.B. Characterization of a novel, membrane-bound, 80-kDa matrixdegrading protease from human breast cancer cells. J. Biol. Chem., 1997, 272(14), 9147-9152.
63. Lin, C.-Y.; Anders, J.; Johnson, M.; Dickson, R.B. Purification and characterization of a complex containing matriptase and a kunitz-type serine protease inhibitor from human milk. J. Biol. Chem., 1999, 274(26), 18237-18242.
64. Takeuchi, T.; Shuman, M. A.; Craik, C.A. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA, 1999, 96(20), 11054-11061.
65. Friedrich, R.; Fuentes-Prior, P.; Ong, E.; Coombs, G.; Hunter, M.; Oehler, R.; Pierson, D.; Gonzalez, R.; Huber, R.; Bode, W.; Madison, E. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J. Biol. Chem., 2002, 277(3), 2160-2168.
66. Oberst, M.D.; Johnson, M.D.; Dickson, R.B.; Lin, C.-Y. Singh, B.; Stewart, M.; Williams, A.; al-Nafussi, A.; Smyth, J.F.; Gabra, H.; Sellar, G.C. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res., 2002, 8(4), 1101-1107.
67. Bhatt, A.S.; Takeuchi, T.; Yistra, B.; Ginzinger, D.; Albertson, D.; Shuman, M.A.; Craik, C.S. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol. Chem., 2003, 384(2), 257-266.
68. Hoang, C.D.; D'Cunha, J.D.; Kratzke, M.G.; Casmey, C.E.; Frizelle, S.P.; Maddaus, M.A.; Kratzke, R.A. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest, 2004 ;125(5), 1843-1852.
69. List, K.; Szabo, R.; Molinolo, A.; Sriuranpong, V.; Redeye, V.; Murdock, T.; Burke, B.; Nielson, B.S.; Gutkind, J.S.; Bugge, T.H. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev., 2005, 19, 1934-1950.
70. Enyedy, I.; Lee, S.-L.; Kuo, A.H.; Dickson, R.B.; Lin, C.-Y.; Wang, S. Structure-based approach for the discovery of bisbenzamidines as novel inhibitors of matriptase. J. Med. Chem., 2001, 44(9), 1349-1355.
71. Long, Y.-Q.; Lee, S.-L.; Lin, C.-Y.; Enyedy, I.; Wang, S.; Li, P.; Dickson, R. B.; Roller, P.P. Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase. Bioorg. Med. Chem. Lett., 2001, 11(18), 2515-2519.
72. Galkin, A.V.; Mullen, L.; Fox, W.D.; Brown, J.; Duncan, D.; Moreno, O.; Madison, E.L.; Agus, D.B. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate, 2004, 61(3), 228-235.
73. Markwardt, F.; Wagner, G.; Stürzebecher, J.; Walsmann, P. N alpha-arylsulfonyl-omega-(4-amidinophenyl)-alpha-aminoalkylcarboxylic acid amides--novel selective inhibitors of thrombin. Thromb. Res., 1980, 17(3-4), 425-431.
74. Stürzebecher, J.; Vieweg, H.; Steinmetzer, T.; Schweinitz, A.; Stubbs, M.T.; Renatus, M.; Wikström, P. 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg. Med. Chem. Lett., 1999, 9(21), 3147-3152.
75. Steinmetzer, T.; Schweinitz, A.; Sturzebecher, A.; Donnecke, D.; Uhland, K.; Schuster, O.; Steinmetzer, P.; Muller, F.; Friedrich, R.; Than, M.E.; Bode, W.; Sturzbecher, J. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J. Med. Chem., 2006, 49(14), 4116-4126.
76. Stürzebecher, J.; Prasa, D.; Hauptmann, J.; Vieweg, H.; Wikström, P. Structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J. Med. Chem., 1997, 40(19), 3091-3099.
77. Korsinczky, M.L.; Schirra, H.J.; Rosengren, K.J.; West, J.; Condie, B.A.; Otvos, L.; Anderson, M.A.; Craik, D.J. Solution structures by 1H NMR of the novel cyclic trypsin inhibitor SFTI-1 from sunflower seeds and an acyclic permutant. J. Mol. Biol., 2001, 311(3), 579-591.
78. Zablotna, E.; Kazmierczak, K.; Jaskiewicz, A.; Stawikowski, M.; Kupryszewski, G.; Rolka, K. Chemical synthesis and kinetic study of the smallest naturally occurring trypsin inhibitor SFTI-1 isolated from sunflower seeds and its analogues. Biochem. Biophys. Res. Commun., 2002, 292(4), 855-859.
79. Descours, A.; Moehle, K.; Renard, A.; Robinson, J.A. A new family of beta-hairpin mimetics based on a trypsin inhibitor from sunflower seeds. Chembiochem, 2002, 3(4), 318-323.
80. Jiang, S.; Li, P.; Lee, S.L.; Lin, C.Y.; Long, Y.Q.; Johnson, M.D.; Dickson, R.B.; Roller, P.P. Design and synthesis of redox stable analogues of sunflower trypsin inhibitors (SFTI-1) on solid support, potent inhibitors of matriptase. Org. Lett., 2007, 9(1), 9-12.
81. Li, P.; Roller, P.P.; Xu, J. Current synthetic approaches to peptide and peptidomimetic cyclization. Curr. Org. Chem., 2002, 6(5), 411-440.
82. Miller, S.J.; Blackwell, H.E.; Grubbs, R.H. Application of ring-closing metathesis to the synthesis of rigidified amino acids and peptides. J. Am. Chem. Soc. 1996, 118(40), 9606-9614.
83. Creighton, C.J.; Reitz, A.B. Synthesis of an eight-membered cyclic pseudo-dipeptide using ring closing metathesis. Org. Lett., 2001, 3(6), 893-895.
84. List, K.; Haudenschild, C.C.; Szabo, R.; Chen, W.J.; Wahl, S.M.; Swaim, W.; Engelholm, L.H.; Behrendt, N.; Bugge, T.H. Matriptase/ MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene, 2002, 21(23), 3765-3779.
85. Vaarala, M.H.; Porvari, K.; Kyllonen, A.; Lukkarinen, O.; Vihko, P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: Detection of mutated TMPRSS2 form in a case of aggressive disease. Int. J. Cancer, 2001, 94(5), 705-710.
86. Sawasaki, T.; Shigemasa, K.; Gu, L.; Beard, J.B. and O'Brien, T.J. The transmembrane protease serine (TMPRSS3/TADG-12) D variant: a potential candidate for diagnosis and therapeutic intervention in ovarian cancer. Tumour Biol., 2004, 25(3), 141-148.
87. Klezovitch, O.; Chevillet, J.; Mirosevich, J.; Roberts, R.L.; Matusik, R.J. and Vasioukhin, V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell, 2004, 6(2), 185-195.
88. Bergeron, F.; Leduc, R. and Day, R. Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. J. Mol. Endocrinol., 2000, 24(1), 1-22.
89. Komiyama, T. and Fuller, R.S. Engineered eglin c variants inhibit yeast and human proprotein processing proteases, Kex2 and furin. Biochemistry, 2000, 39(49), 15156-15165.
90. Liu, Z.X.; Fei, H. and Chi, C.W. Two engineered eglin c mutants potently and selectively inhibiting kexin or furin. FEBS Lett., 556(3), 116-120.
91. Komiyama, T.; VanderLugt, B.; Fugere, M.; Day, R.l; Kaufman, R.J. and Fuller, R.S. Optimization of protease-inhibitor interactions by randomizing adventitious contacts. Proc. Natl. Acad. Sci. USA, 2003, 100(14), 8205-8210.
92. Li, A. and Daggett, V. Investigation of the solution structure of chymotrypsin inhibitor 2 using molecular dynamics: comparison to X-ray crystallographic and NMR data. Protein Eng., 1995, 8(11), 1117-1128.
93. Hyberts, S.G.; Goldberg, M.S.; Havel, T.F. and Wagner, G. The solution structure of eglin c based on measurements of many NOEs and coupling constants and its comparison with X-ray structures. Protein Sci., 1992, 1(6), 736-751.
94. Baici, A. and Seemuller, U. Kinetics of the inhibition of human leucocyte elastase by eglin from the leech Hirudo medicinalis. Biochem. J., 1984, 218, 829-833.
95. Ascenzi, P.; Amiconi, G.; Menegatti, E.; Guarneri, M.; Bolognesi, M. and Schnebli, H.P. Binding of the recombinant proteinase inhibitor eglin c from leech Hirudo medicinalis to human leukocyte elastase, bovine alpha-chymotrypsin and subtilisin Carlsberg: thermodynamic study. J Enzyme Inhib., 1988, 2(3), 167-172.
96. Heinz, D.W.; Hyberts, S.G.; Peng, J.W.; Priestle, J.P.; Wagner, G. and Grutter, M.G. Changing the inhibitory specificity and function of the proteinase inhibitor eglin c by site-directed mutagenesis: functional and structural investigation. Biochemistry, 1992, 31(37), 8755-8766.
97. Cai, X.H.; Zhang, Q.; Ding, D.F. Rational redesign of inhibitors of furin/kexin processing proteases by electrostatic mutations. Acta Pharmacol. Sin., 2004, 25(12), 1712-1718.
98. Desilets, A.; Longpre, J.M.; Beaulieu, M.E.; Leduc, R. Inhibition of human matriptase by eglin c variants. FEBS Lett., 2006, 580(9), 2227-2232.
99. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2(3), 163-174.
100. Coussens, L.; Werb, Z. Matrix metalloproteinases and the development of cancer. Chem. Biol., 1996, 3(11), 895-904.
101. Mannello, F.; Luchetti, F.; Falcieri, E.; Papa, S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis, 2005, 10(1), 19-24.
102. Mannello, F.; Gazzanelli, G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis, 2001, 6(6), 479-482.
103. Luchetti, F.; Mannello, F.; Canonico, B.; Battistelli, M.; Burattini, S.; Falcieri, E.; Papa, S. Integrin and cytoskeleton behaviour in human neuroblastoma cells during hyperthermia-related apoptosis. Apoptosis, 2004, 9(5), 635-648.
104. Stamenkovic, I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J. Pathol., 2003, 200(4), 448-464.
105. Vihinen, P.; Kahari, V.-M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer, 2002, 99(2), 157-166.
106. Overall, C.; Lopez-Otìn, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer, 2002, 2(9), 657-672.
107. Mannello F, Tonti, G.; Papa, S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr. Cancer Drug Target, 2005, 5(4), 285-298.
108. Murphy, G.; Willenbrock, F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol., 1995, 248, 496-510.
109. Coussens, L.M.; Fingleton, B.; Matrisian, L. Matrix metalloproteinase inhibitors and cancer - trials and tribulations. Science, 2002, 295(5564), 2387-2392.
110. Borkakoti, N. Matrix metalloprotease inhibitors: design from structure. Biochem. Soc. Trans., 2004, 32(Pt 1), 17-20.
111. Hutchinson, J.W.; Tierney, G.M.; Parson, S. L.; Davis, T.R.C. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J. Bone Joint Surg. Br., 1998, 80(B), 907-908.
112. Holmbeck, K.; Bianco, P.; Caterina, J.; Yamada, S.; Kromer, M.; Kuznetsov, S.A.; Mankani, M.; Robey, P.G.; Poole, A.R.; Pidoux, I.; Ward, J.M.; Birkedal-Hansen, H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell, 1999, 99(1), 81-92.
113. Steward, W. P. Marimastat (BB2516): current status of development. Cancer Chemother. Pharmacol., 1999, 43, S56-S60.
114. Dahlberg, L.; Billinghurst, R.C.; Manner, P.; Nelson, F.; Webb, G.; Ionescu, M.; Reiner, A.; Tanzer, M.; Zukor, D.; Chen, J.; Van Wart, H.E.; Poole, A.R. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum., 2000, 43(3), 673-682.
115. Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C.T. Anti-cancer and antiviral sulfonamides. Curr. Med. Chem., 2003, 10(11), 925-953.
116. Supuran, C.T.; Casini, A.; Scozzafava, A. Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Med. Res. Rev., 2003, 23(5), 535-558.
117. Supuran, C.T.; Scozzafava, A. In Proteinase and Peptidase Inhibitors: Recent Potential Targets for Drug Development; Smith, H.J., Simons, C., Eds.; Taylor & Francis: London & New York, 2002; pp. 35-61.
118. Nyormoi, O.; Mills, L.; Bar-Eli, M. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ., 2003, 10(5), 558-569.
119. Murphy, G.; Crabbe, T. Gelatinases A and B. Methods Enzymol., 1995, 248, 470-484.
120. Lafleur, M.A.; Forsyth, P.A.; Atkinson, S.J.; Murphy, G.; Edwards, D.R. Perivascular cells regulate endothelial membrane Type-1 matrix metalloproteinase activity. Biochem. Biophys. Res. Commun., 2001, 282(2), 463-473.
121. Tu, G.; Xu, W.; Huang, H.; Li, S. Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem., 2008, 15(14), 1388-1395.
122. Matziari, M.; Dive, V.; Yiotakis, A. Matrix metalloproteinase 11 (MMP-11; stromelysin-3) and synthetic inhibitors. Med. Res. Rev., 2007, 27(4), 528-552.
123. Whittaker, M.; Floyd, C.D.; Brown, P.; Gearing, J.H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev., 1999, 99(9), 2735-2776.
124. Rossello, A.; Nuti, E.; Orlandini, E.; Carelli, P.; Rapposelli, S.; Macchia, M.; Minutolo, F.; Carbonaro, L.; Albini, A.; Benelli, R.; Cercignani, G.; Murphy, G.; Balsamo, A. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg. Med. Chem., 2004, 12(9), 2441-2450.
125. Overall, C.M.; Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer, 2006, 94(7), 941-946.
126. Maquoi, E.; Frankenne, F.; Baramova, E.; Munaut, C.; Sounni, N.E.; Remacle, A.; Noel, A.; Murphy, G.; Foidart, J.M. Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines. J. Biol. Chem., 2000, 275(15), 11368-11378.
127. Sounni, N.E.; Roghi, C.; Chabottaux, V.; Janssen, M.; Munaut, C.; Maquoi, E.; Galvez, B.G.; Gilles, C.; Frankenne, F.; Murphy, G.; Foidart, J.-M.; Noel, A. Up-regulation of vascular endothelial growth factor-a by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J. Biol. Chem., 2004, 279(14), 13564-13574.
128. Ikejiri, M.; Bernardo, M.M.; Bonfil, R.D.; Toth, M.; Chang, M.L.; Fridman, R.; Mobashery, S. Potent mechanism-based inhibitors for matrix metalloproteinases. J. Biol. Chem., 2005, 280(40), 33992-34002.
129. Duggleby, R.G.; Attwood, P.V.; Wallace, J.C.; Keech, D.B. Avidin is a slow-binding inhibitor of pyruvate carboxylase. Biochemistry, 1982, 21(14), 3364-3370.
130. Morrison, J.F. Walsh, C.T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol., 1988, 61, 201-301.
131. Szedlacsek, S.E.; Duggleby, R.G. Kinetics of slow and tight-binding inhibitors. Methods Enzymol., 1995, 249, 144-180.
132. Kleifeld, O.; Kotra, L.P.; Gervasi, D.C.; Brown, S.; Bernardo, M.M.; Fridman, R.; Mobashery, S.; Sagi, I. X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. Comparison with the latent and active forms of the enzyme. J. Biol. Chem., 2001, 276(20), 17125-17131.
133. Strongin, A.Y.; Marmer, B.L.; Grant, G.A.; Goldberg, G.I. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J. Biol. Chem., 1993, 268(19), 14033-14039.
134. Strongin, A.Y.; Collier, I.; Bannikov, G.; Marmer, B.L.; Grant, G.A.; Goldberg, G.I. Mechanism of cell surface activation of 72-kda type iv collagenase. J. Biol. Chem., 1995, 270(10), 5331-5338.
135. Toth, M.; Bernardo, M.M.; Gervasi, D.C.; Soloway, P.D.; Wang, Z.; Bigg, H.F.; Overall, C.M.; DeClerck, Y.A.; Tschesche, H.; Cher, M.L.; Brown, S.; Mobashery, S.; Fridman, R. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane Type 1)-MMP-dependent activation of pro-MMP-2. J. Biol. Chem., 2000, 275(52), 41415-41423.
136. Muller, D.; Wolf, C.; Abecassis, J.; Millon, R.; Engelmann, A.; Bronner, G.; Rouyer, N.; Rio, M.C.; Eber, M.; Methlin, G.; Chambon, P.; Basset, P. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinoma. Cancer Res., 1993, 53, 165-169.
137. Porte, H.; Chastre, E.; Prevot, S.; Nordlinger, B.; Empereur, S.; Basset, P.; Chambon, P.; Gespach C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int. J. Cancer, 1995, 64(1), 70-75.
138. Thewes, M.; Worret, W.I.; Engst, R.; Ring, J. Stromelysin-3 (ST-3): immunohistochemical characterization of the matrix metallo-proteinase (MMP)-11 in benign and malignant skin tumours and other skin disorders. Clin. Exp. Derinatol., 1999, 24(2), 122-126.
139. Rouyer, N.; Wolf, C.; Chenard, M.P.; Rio, M.C.; Chambon, P.; Bellocq, J.P.; Basset, P. Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis, 1994, 14(1-6), 269-275.
140. Rio, M.C. From a unique cell to metastasis is a long way to go: clues to stromelysin-3 participation. Biochimie, 2005, 87(3-4), 299-306.
141. Wolf, C.; Chenard, M.P.; Durand de Grossouvre, P.; Bellocq, J.P.; Chambon, P.; Basset, P. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J. Invest. Dermatol., 1992, 99(6), 870-872.
142. Lefebvre, O.; Regnier, C.; Chenard, M.P.; Wendling, C.; Chambon, P.; Basset, P.; Rio, M.C. Developmental expression of mouse stromelysin-3 mRNA. Development, 1995, 121(4), 947-955.
143. Berry, D.L.; Rose, C.S.; Remo, B.F.; Brown, D.D. The expression pattern of thyroid hormone response genes in remodeling tadpole tissues defines distinct growth and resorption gene expression programs. Dev. Biol., 1998, 203(1), 24-35.
144. Hagglund, A.C.; Ny, A.; Leonardsson, G.; Ny, T. Regulation and localization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse ovary during gonadotropin-induced ovulation. Endocrinology, 1999, 140(9), 4351-4358.
145. Acharya, K.R.; Sturrock, E.D.; Riordan, J.F.; Ehlers, M.R. ACE revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov., 2003, 2, 891-902.
146. Molinaro, G.; Rouleau, J-L.; Adam, A. Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics. Curr. Opin. Pharm., 2002, 2(2), 131-141.
147. Lopez-Otin, C.; Overall, C.M. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol., 2002, 3(7), 509-519.
148. Turk, B.E.; Wong, T.Y.; Schwarzenbacher, R.; Jarrell, E.T.; Leppla, S.H.; Collier, R.J.; Liddington R.C.; Cantley, L.C. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol., 2004, 11(1), 60-66.
149. Peng, S.X.; Strojnowski, M.J.; Hu, J.K.; Smith, B.J.; Eichhold, T.H.; Wehmeyer, K.R.; Pikul, S.; Almstead, N.G. Gas chromatographic-mass spectrometric analysis of hydroxylamine for monitoring the metabolic hydrolysis of metalloprotease inhibitors in rat and human liver microsomes. J. Chromatogr. B Biomed. Sci. Appl., 1999, 724(1), 181-187.
150. Junot, C.; Gonzales, M.F.; Ezan, E.; Cotton, J.; Vazeux, G.; Michaud, A.; Azizi, M.; Vassiliou, S.; Yiotakis, A.; Corvol, P.; Dive, V. RXP 407, a Selective inhibitor of the n-domain of angio-tensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide Acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J. Pharmacol. Exp. Ther., 2001, 297(2), 606-611.
151. Georgiadis, D.; Beau, F.; Czarny, B.; Cotton, J.; Yiotakis, A.; Dive, V. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ. Res., 2003, 93(2), 148-154.
152. Cursio, R.; Mari, B.; Louis, K.; Rostagno, P.; Saint-Paul, M.C.; Giudicelli, J.; Bottero,V.; Anglard, P.;Yiotakis, A.; Dive, V.; Gugenheim, J.; Auberger, P. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J., 2002, 16, 93.
153. Buchardt, J.; Schiodt, C.B.; Krog-Jensen, C.; Delaisse, J.M.; Foged,
154. Reiter, L.A.; Rizzi, J.P.; Pandit, J.; Lasut, M.J.; McGahee, S.M.; Parikh, V.D.; Blake, J.F. Danley, D.E.; Laird, E.R.; Lopez-Anaya, A.; Lopresti-Morrow, L.L.; Mansour, M.N.; Martinelli, G.J.; Mitchell, P.G.; Owens, B.S.; Pauly, T.A.; Reeves, L.M.; Schulte, G.K.; Yocum, S.A. Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket. Bioorg. Med. Chem. Lett., 1999, 9(2), 127-132.
155. Schiødt, C.B.; Buchardt, J.; Terp, G.E.; Christensen, U.; Brink, M.; Larsen, Y.B.; Meldal, M.; Foged, N.T. Phosphinic peptide inhibitors of macrophage metalloelastase (MMP-12): Selectivity and mechanism of binding. Curr. Med. Chem., 2001, 8(8), 967-976.
156. Yiotakis, A.; Georgiadis, D.; Matziari, M.; Makaritis, A.; Dive, V. Phosphinic peptides: Synthetic approaches and biochemical evaluation as Zn-metalloprotease inhibitors. Curr. Org. Chem., 2004, 8(12), 1135-1158.
157. Dive, V.; Georgiadis, D.; Matziari, M.; Makaritis, A.; Beau, F.; Cuniasse, P.; Yiotakis, A. Phosphinic peptides as zinc metalloproteinase inhibitors. Cell. Mol. Life. Sci., 2004, 61(16), 2010-2019.
158. Yiotakis, A.; Vassiliou, S.; Jiracek, J.; Dive, V. Protection of the hydroxyphosphinyl function of phosphinic dipeptides by adamantyl. application to the solid-phase synthesis of phosphinic peptides. J. Org. Chem., 1996, 61(19), 6601-6605.
159. Matziari, M.; Yiotakis, A. Shortcut to fmoc-protected phosphinic pseudodipeptidic blocks. Org. Lett., 2005, 7(18), 4049-4052.
160. Matziari, M.; Georgiadis, D.; Dive, V.; Yiotakis, A. Convenient synthesis and diversification of dehydroalaninyl phosphinic peptide analogues. Org. Lett., 2001, 3(5), 659-662.
161. Makaritis, A.; Georgiadis, D.; Dive, V.; Yiotakis, A. Diastereoselective solution and multipin-based combinatorial array synthesis of a novel class of potent phosphinic metalloprotease inhibitors. Chem. Eur. J., 2003, 9(9), 2079-2094.
162. Hamuro,Y.; Marshall, W.J.; Scialdone, M.A. Solid-phase synthesis of acyclic and cyclic amino acid derived urea peptidomimetics using phoxime resin. J. Comb. Chem., 1999, 1(2), 163-172.
163. Buhlling, F.; Fengler, A.; Brandt, W.; Welte, T.; Ansorge, S.; Nagler, D.K. Review: novel cysteine proteases of the papain family. Adv. Exp. Med. Biol., 2000, 477, 241-254.
164. Turk, V.; Turk, B.; Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J., 2001, 20(17), 4629-4633.
165. Elliott, E.; Sloane B.F. The cysteine protease cathepsin B in cancer. Persp. Drug. Disc. Des., 1996, 6(1), 12-32.
166. Vasiljeva, O.; Reinheckel, T.; Petres, C.; Turk, D.; Turk, V.; Turk, B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des., 2007, 13(4), 387-403.
167. Turk, D.; Gunčar, G. Lysosomal cysteine proteases (cathepsins) : promising drug targets. Acta Crystallogr. D Biol. Crystallogr., 2003, 59(Pt 2), 203-213.
168. Turk, V.; Turk, B.; Gunčar, G.; Turk, D.; Kos, J. Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv. Enzym. Regul., 2002, 42, 285-303.
169. Leung-Toung, R.; Zhao, Y.; Li, W.; Tam, T.F.; Karimian, K.; Spino, M. Thiol proteases: inhibitors and potential therapeutic targets. Curr. Med. Chem., 2006, 13(5), 547-581.
170. Otto, H.-H.; Schirmeister, T. Cysteine proteases and their inhibitors. Chem. Rev., 1997, 97(1), 133-172.
171. Leung, D.; Abbenante, G.; Fairlie, D.P. Protease inhibitors: current status and future prospects. J. Med. Chem., 2000, 43(3), 305-341.
172. Hernandez, A.A.; Roush, W.R. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr. Opin. Chem. Biol., 2002, 6(4), 459-465.
173. Powers, J.C.; Asgian, J.L.; Ekici, O.D.; James, K.E. Irreversible inhibitors of serine, cysteine and threonine proteases. Chem. Rev., 2002, 102, 4639.
174. Frlan, R.; Gobec, S. Inhibitors of cathepsin B. Curr. Med. Chem., 2006, 13(19), 2309-2327.
175. Vicik, R.; Busemann, M.; Baumann, K.; Schirmeister, T. Inhibitors of cysteine proteases. Curr. Top. Med. Chem., 2006, 6(4), 331-353.
176. Anderson, A.C. The process of structure-based drug design. Chem. Biol., 2003, 10(9), 787-797.
177. Falgueyret, J.P.; Black, W.C.; Cromlish, W.; Desmarais, S.; Lamontagne, S.; Mellon, C.; Riendeau, D.; Rodan, S.; Tawa, P.; Wesolowski, G.; Bass, K.E.; Venkatraman, S.; Percival, M.D. An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells. Anal. Biochem., 2004, 335(2), 218-227.
178. Methot, N.; Vaillancourt, J.P.; Huang, J.; Colucci, J.; Han, Y.; Menard, S.; Zamboni, R.; Toulmond, S.; Nicholson, D.W.; and Roy, S. A caspase active site probe reveals high fractional inhibition needed to block DNA fragmentation. J. Biol. Chem., 2004, 279(27), 27905-27914.
179. Speers, A.E.; and Cravatt, B.F. Profiling enzyme activities in vivo using click chemistry methods. Chem. Biol., 2004, 11(4), 535-546.
180. Hanada, K.; Tamai, M.; Yamagishi, M.; Ohmura, S.; Sawada, J.; Tanaka, I. Isolation and characterization of E-64, a new thiol protease inhibitor. Agric. Biol. Chem., 1978, 42(3), 523-528.
181. Miyahara, T.; Shimojo; S.; Toyohara, K.; Imai, T.; Miyajima, M.; Honda, H.; Kamegai, M.; Ohzeki, M.; Kokatsu, J. Phase I study of EST, a new thiol protease inhibitor--The second report: Safety and pharmacokinetics in continuous administration. Jpn. J. Clin. Pharmacol. Ther., 1985, 16, 537-546.
182. Tachikura, T. The teratogenic effects of E-64 on rat embryogenesis. Acta Paediatr. Jpn., 1990, 32(5), 495-501.
183. Fukushima, K.; Arai, M.; Kohno, Y.; Suwa, T.; Satoh, T. An epoxysuccinic acid derivative(loxistatin)-induced hepatic injury in rats and hamsters. Toxicol. Appl. Pharmacol., 1990, 105(1), 1-12.
184. Schaschke, N.; Assfalg-Machleidt, I.; Machleidt, W.; Moroder, L. Substrate/propeptide-derived endo-epoxysuccinyl peptides as highly potent and selective cathepsin B inhibitors. FEBS Lett., 1998, 421(1), 80-82.
185. Verhelst, S.H.; and Bogyo, M. Solid-phase synthesis of double-headed epoxysuccinyl activity-based probes for selective targeting of papain family cysteine proteases. Chembiochem, 2005, 6(5), 824-827.
186. Katunuma, N., Murata, E., Kakegawa, H., Matsui, A., Tsuzuki, H., Tsuge, H., Turk, D., Turk, V., Fukushima, M., Tada, Y., and Asao, T. Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo. FEBS Lett., 1999, 458(1), 6-10.
187. Schaschke, N.; Deluca, D.; Assfalg-Machleidt, I.; Hohneke, C.; Sommerhoff, C. P.; Machleidt, W. Epoxysuccinyl peptide-derived cathepsin B inhibitors: modulating membrane permeability by conjugation with the C-terminal heptapeptide segment of penetratin. Biol. Chem., 2002, 383(5), 849-852.
188. Schaschke, N.; Assfalg-Machleidt, I.; Machleidt, W.; Lassleben, T.; Sommerhoff, C.P.; Moroder, L. β-Cyclodextrin-epoxysuccinyl peptide conjugates: a new drug targeting system for tumor cells. Bioorg. Med. Chem. Lett., 2000, 10(7), 677-680.
189. Schaschke, N.; Assfalg-Machleidt, I.; Lassleben, T.; Sommerhoff, C.P.; Moroder, L.; Machleidt, W. Epoxysuccinyl peptide-derived affinity labels for cathepsin B. FEBS Lett., 2000, 482(1-2), 91-96.
190. Schaschke, N., Assfalg-Machleidt, I., Machleidt, W., Turk, D., and Moroder, L. E-64 analogues as inhibitors of cathepsin B. On the role of the absolute configuration of the epoxysuccinyl group. Bioorg. Med. Chem., 1997, 5(9), 1789-1797.
191. Eilon, G.F.; Gu, J.; Slater, L.M.; Hara, K.; Jacobs, J.W. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents. Cancer Chemother. Pharmacol., 2000, 45(3), 183-191.
192. Anonymous. Information update NCO-700. Drugs Fut., 2000, 25(11), 1215.
193. Sadaghiani, A.M.; Verhelst, S.H.L.; Gocheva, V.; Hill, K.; Majerova, E.; Stinson, S.; Joyce, J.A. Bogyo, M. Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases. Chem. Biol., 2007, 14(5), 499-511.
194. Greenbaum, D.C.; Arnold, W.D.; Lu, F.; Hayrapetian, L.; Baruch, A.; Krumrine, J.; Toba, S.; Chehade, K.; Brèomme, D.; Kuntz, I.D.; Bogyo, M. Small molecule affinity fingerprinting. A tool for enzyme family subclassification, target identification, and inhibitor design. Chem. Biol., 2002, 9(10), 1085-1094.
195. Greenbaum, D., Medzihradszky, K. F., Burlingame, A.; Bogyo, M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem. Biol., 2000, 7(8), 569-581.
196. Leung, D.; Hardouin, C.; Boger, D.L.; and Cravatt, B.F. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol., 2003, 21(6), 687-691.
197. Harris, J.L.; Backes, B.J.; Leonetti, F.; Mahrus, S.; Ellman, J.A.; Craik, C.S. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl. Acad. Sci. USA, 2000, 97(14), 7754-7759.
198. Waldmeier, P. C.; Maître, L.; Baumann, P. A.; Hauser, K.; Bischoff, S.; Bittiger, H.; Paioni, R. Ifoxetine, a compound with atypical effects on serotonin uptake. Eur. J. Pharmacol., 1986, 130(1-2), 1-10.
199. Paioni, R.; Waldmeier, P.C.; Delini-Stula, A. Ifoxetifne sulfate. Drugs Future, 1987, 12, 126.
200. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 2004, 5(5), 417.
201. Coux, O.; Tanaka, K.; Goldberg, A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem., 1996, 65, 801-847.
202. Larsen, C.N.; Finley, D. Protein translocation channels in the proteasome and other proteases. Cell, 1997, 91(4), 431-434.
203. Baumeister, W.; Walz, J.; Zühl, F.; Seemüller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell, 1998, 92(3), 367-380.
204. Orlowski, M.; Wilk, S. A multicatalytic protease complex from pituitary that forms enkephalin and enkephalin containing peptides. Biochem. Biophys. Res. Commun., 1981, 101(3), 814-822.
205. Iqbal, M.; Chatterjee, S.; Kauer, J.C.; Mallamo, J.P.; Messina, P.A.; Reibolt, A. Simon, R. Potent α-ketocarbonyl and boronic ester de rived inhibitors of proteasome. Biorg. Med. Chem. Lett., 1996, 6(3), 287-290.
206. Adams, J.; Behnke, M.; Chen, S.; Cruickshank, A.A.; Dick, L.R.; Grenier, L.; Klunder, J.M.; Ma, Y.T.; Plamondon, L.; Stein, R.L. Proteasome inhibitors: from research tools to drug candidates. Bioorg. Med. Chem. Lett., 1998, 8(4), 333-338.
207. Kisselev, A.F.; and Goldberg, A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol., 2001, 8(8), 739-758.
208. Rock, K.L.; Gramm, C.; Rothstein, L.; Clark, K.; Stein, R.; Dick, L.; Hwang, D.; Goldberg, A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 1994, 78(5), 761-771.
209. Iqbal, M.; Chatterjee, S.; Kauer, J.C.; Das, M.; Messina, P.; Freed, B.; Biazzo, W.; Siman, R. Potent inhibitors of proteasome. J. Med. Chem., 1995, 38(13), 2276-2277.
210. Zuckermann, R.N.; Kerr, J. M.; Kent, S.B.H., Moos, W.H.J. Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis. J. Am. Chem. Soc., 1992, 114(26), 10646-10647.
211. Kessler, H. Peptoids - a new approach to the development of key pharmaceuticals. Angew. Chem. Int. Ed. Engl., 1993, 32(4), 543-544.
212. Dutta, A.S.; Morley, J.S. Polypeptides. Part XIII. Preparation of α-aza-amino-acid (carbazic acid) derivatives and intermediates for the preparation of α-aza-peptides. J. Chem. Soc., Perkin Trans. 1, 1975, 17, 1712-1720.
213. Gante, J. Azapeptides. Synthesis, 1989, 6, 405-413.
214. Quibell, M.; Turnell, W. G.; Johnson, T. J. Synthesis of azapeptides by the Fmoc/tert-butyl/polyamide technique. J. Chem. Soc., Perkin Trans. 1, 1993, 2843-2849.
215. Han, H.; Janda, K.D. Azatides: solution and liquid phase syntheses of a new peptidomimetic. J. Am. Chem. Soc., 1996, 118(11), 2539-2544.
216. Kruijtzer, J.A.W.; Lefeber, D.J.; Liskamp, R.M.J. Approaches to the synthesis of ureapeptoid peptidomimetics. Tetrahedron Lett., 1997, 38(30), 5335-5338.
217. Shin, I.; Park, K. Solution-phase synthesis of aminooxy peptoids in the C to N and N to C directions. Org. Lett., 2002, 4(6), 869-872.
218. Hamper, B.C.; Kolodziej, S.A.; Scates, A.M.; Smith, R.G.; Cortez, E. Solid phase synthesis of β-peptoids: N-substituted β-aminopropionic acid oligomers. J. Org. Chem., 1998, 63(3), 708-718.
219. Cheguillaume, A.; Lehardy, F.; Bouget, K.; Baudy-Floc'h, M.; Le Grel, P. Submonomer solution synthesis of hydrazinoazapeptoids, a new class of pseudopeptides. J. Org. Chem., 1999, 64(8), 2924-2927.
220. Kruijtzer, J.A.; Hofmeyer, L.J.F.; Herma, W.; Verluis, C.; Liskamp, R.M.J. Solid-phase syntheses of peptoids using Fmocprotected N-substituted glycines: The synthesis of (retro)peptoids of leu-enkephalin and substance P. Chem. Eur. J., 1998, 4(8), 1570-1580.
221. Aubin, S.; Martin, B.; Delcros, J.-G.; Arlot-Bonnemains, Y.; Baudy-Floc'h, M. Retro hydrazino-azapeptoids as peptidomimetics of proteasome inhibitors. J. Med. Chem., 2005, 48(1), 330-334.
222. Teicher, B.A.; Ara, G.; Herbst, R.; Palombella, V.J.; Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res., 1999, 5(9), 2638-2645.
223. Lightcap, E.S.; McCormack, T.A.; Pien, C.S.; Chau, V.; Adams, J.; Elliott, P.J. Proteasome inhibition measurements: clinical application. Clin. Chem., 2000, 46(5), 673-683.
224. Palmer, J.T.; Rasnick, D.; Klaus, J.L.; Brömme, D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem., 1995, 38(17), 3193-3196.
225. Brömme, D.; Klaus, J.L.; Okamoto, K.; Rasnick, D.; Palmer, J.T. Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem. J., 1996, 315(Pt 1), 85-89.
226. Bogyo, M.; McMaster, J.S.; Gaczynska, M.; Tortorella, D.; Goldberg, A.L.; Ploegh, H. Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homologue HsIV by a new class of inhibitors. Proc. Natl. Acad. Sci. USA, 1997, 94(13), 6629-6634.
227. Palmer, J.T.; Bryant, C.; Wang, D.-X.; Davis, D.E.; Setti, E.L.; Rydzewski, R.M.; Venkatraman, S.; Tian, Z.-Q.; Burrill, L.C.; Mendonca, R.V.; Springman, E.; McCarter, J.; Chung, T.; Cheung, H.; Janc, J. W.; McGrath, M.; Somoza, J.R.; Enriquez, P.; Yu, Z.W.; Strickley, R.M.; Liu, L.; Venuti, M.C.; Percival, M.D.; Falgueyret, J.-P.; Prasit, P.; Oballa, R.; Riendeau, D.; Young, R.N.; Wesolowski, G.; Rodan, S.B.; Johnson, C.; Kimmel, D.B.; Rodan, G. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J. Med. Chem., 2005, 48(24), 7520-7534.
228. Bogyo, M.; Shin, S.; McMaster, J.S.; Ploegh, H. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol., 1998, 5(6), 307-320.
229. Rydzewski, R.M.; Burrill, L.; Mendonca, R.; Palmer, J.T.; Rice, M.; Tahilramani, R.; Bass, K.E.; Leung, L.; Gjerstad, E.; Janc, J.W.; Pan, L. Optimization of subsite binding to the β5 subunit of the human 20S proteasome using vinyl sulfones and 2-Keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors. J. Med. Chem., 2006, 49(10), 2953-2968.
230. Ohmoto, K.; Yamamoto, T.; Okuma, M.; Horiuchi, T.; Imanishi, H.; Odagaki, Y.; Kawabata, K.; Sekioka, T.; Hirota, Y.; Matsuoka, S.; Nakai, H.; Toda, M. Development of orally active nonpeptidic inhibitors of human neutrophil elastase. J. Med. Chem., 2001, 44(8), 1268-1285.
231. Perni, R.B.; Pitlik, J.; Britt, S.D.; Court, J.J.; Courtney, L.F.; Deininger, D.D.; Farmer, L.J.; Gates, C.A.; Harbeson, S.L.; Levin, R.B.; Lin, C.; Lin, K.; Moon, Y.-C.: Luong, Y.-P.; O'Malley, E. T.; Rao, B.G.; Thomson, J.A.; Tung, R.D.; Van Drie, J.H.; Wei, Y. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization. Bioorg. Med. Chem. Lett., 2004, 14(6), 1441-1446.
232. Wacher, V.J.; Silverman, J.A.; Zhang, Y.; Benet, L.Z. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 1998, 87(11), 1322-1330.
233. Imbach, P.; Lang, M.; García-Echeverría, C.; Guagnano, V.; Noorani, M.; Roesel, J.; Bitsch, F.; Rihs G.; Furet, P. Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorg. Med. Chem. Lett., 2007, 17(2), 358-362.
234. García-Echeverría, C. Peptide and peptide-like modulators of 20S proteasome enzymatic activity in cancer cells. Int. J. Pept. Res. Ther., 2006, 12(1), 49-64.
235. Delcros, J.; Baudy Floc'h, M.; Prigent, C.; Arlot-bonnemains, Y. proteasome inhibitors as therapeutic agents: current and future strategies. Curr. Med. Chem., 2003, 10(6), 479-503.
236. García-Echeverría, C. Recent advances in the identification and development of 20S proteasome inhibitors. Mini-Rev. Med. Chem., 2002, 2(3), 247-259.
237. Nawrocki, S.; Bruns, C.; Harbison, M.; Bold, R.; Gotsch, B.; Abbruzzese, J.; Elliott, P.; Adams, J.; McConkey, D. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther., 2002, 1(14), 1243-1253.
238. Furet, P.; Imbach, P.; Noorani, M.; Koeppler, J.; Laumen, K.; Lang, M.; Guagnano, V.; Fuerst, P.; Roesel, J.; Zimmermann, J.; Garcia-Echeverría, C. Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design. J. Med. Chem., 2004, 47(20), 4810-4813.
239. Vispé, S.; Vandenberghe, I.; Robin, M.; Annereau, J.P.; Créancier, L.; Pique, V.; Galy, J.P.; Kruczynski, A.; Barret, J. M.; Bailly, C. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Biochem. Pharmacol., 2007, 73(12), 1863-1872.
240. Demeunynck, M.; Charmantray, F.; Martelli, A. Interest of acridine derivatives in the anticancer chemotherapy. Curr. Pharm. Des., 2001, 7(17), 1703-1724.
241. Denny, W.A. Acridine derivatives as chemotherapeutic agents. Curr. Med. Chem., 2002, 9(18), 1655-1665.
242. Figueiredo-Pereira, M.E.; Chen W.E.; Li, J.; Johdo, O. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiq uitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J. Biol. Chem., 1996, 271(28), 16455-16459.
243. Narazaki, M.; Tosato, G. Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth? J. Natl. Cancer Inst., 2006, 98(11), 726-727.
244. Fingleton, B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin. Ther. Targets, 2003, 7(3), 385-397.
245. Merchan, J.R.; Tang, J.; Hu, G.; Lin, Y.; Mutter, W.; Tong, C.; Karumanchi, S.A.; Russell, S. J.; Sukhatme, V.P. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J. Natl. Cancer Inst., 2006, 98(11), 756-764.
246. Verills, N.M. Clinical proteomics: present and future prospects. Clin. Biochem. Rev., 2006, 27(2), 99-116.
247. Duffy, M.J.; Lynn, D.J.; Lloyd, A.T.; O'Shea C.M. The ADAMs family of proteins: from basic studies to potential clinical applications. Thromb. Haemost., 2003, 89(4), 622-631.